Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement

Vancouver, Canada -- Nortran Pharmaceuticals Inc., the Canadian drug discovery company, and Hoechst Marion Roussel ("Hoechst"), the global pharmaceutical subsidiary of Hoechst AG, today announced the signing of a collaborative agreement in the area of cardiac arrhythmias. This collaboration will capitalize on the complementary expertise of the two companies in this area.

Under the terms of the agreement Nortran and Hoechst Marion Roussel will test investigational antiarrhythmic compounds developed by both companies. The companies will evaluate the pharmacological profiles of their compounds through the use of both companies' proprietary electrophysiological models and other preclinical tests.

"We are delighted to be working with a company of Hoechst Marion Roussel's calibre who have demonstrated their leadership in the field of cardiovascular therapeutics," commented Bob Rieder, President and Chief Executive Officer of Nortran. "We are confident that this agreement will give fresh impetus to the field of antiarrhythmic drugs and create new opportunities that will benefit both the pharmaceutical industry and ultimately patients with the condition."

Nortran recently presented findings of its preclinical research on atrial fibrillation at the European Congress of Pharmacology in Budapest. "The drugs we have developed exhibit unique pharmacological properties which may lead to a new class of antiarrhythmic drug, " said Greg Beatch, Vice President Research, Nortran. "The heart rate dependent activity of our molecules is the basis for safe, effective antiarrhythmic drugs. We are very excited about the potential for our new class of antiarrhythmics. Our collaboration with Hoechst Marion Roussel can only expedite our research program."

Hoechst Marion Roussel, a world leader in pharmaceutical-based health care, is dedicated to extending human life and enhancing its quality through the discovery, development, manufacture and sale of pharmaceutical produ

Contact: Asa Zanatta
Contemporary Communications

Page: 1 2

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
5. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
6. Pharmaceuticals and personal care products
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. The Gerontological Society of America announces Hartford Fellowship recipients
11. TB Alliance announces new drug discovery program with GlaxoSmithKline

Post Your Comments:

(Date:12/5/2018)... ... , ... Body by Ravi Plastic Surgery and Aesthetics is ... offer the BodyTitePRO treatment. Dr. Ravi Somayazula , practice founder, has dedicated ... techniques to improve the face, breast and body. Together with his partner, Swapna ...
(Date:12/5/2018)... DEERFIELD, Ill. (PRWEB) , ... December 05, 2018 ... ... providing CRO, FSP, Strategic Resourcing, and Consulting services, announced its new office location ... location will accommodate organic growth of clinical trial operations in Europe and additional ...
(Date:12/5/2018)... ... December 05, 2018 , ... ... Group (HM). In this role, he will be responsible for the executive oversight ... , “We conducted an extensive, nationwide search for this position,” Tom Doran, president, ...
(Date:11/29/2018)... ... November 29, 2018 , ... ... and treat chronic pain without opiates. This new and unique approach to the ... eliminate chronic pain for both children and adults. , According to CPARF’s ...
(Date:11/28/2018)... ... November 28, 2018 , ... Shareholders Lori G. Cohen ... Greenberg Traurig, LLP are speaking at the 23rd Annual American Conference Institute (ACI) Conference ... York City from Nov. 28 through Nov. 30 at the New York Marriott Marquis. ...
Breaking Medicine News(10 mins):
(Date:11/29/2018)... ... 29, 2018 , ... Cantata Health, a leading provider of ... care, post-acute care, and long-term care facilities, announced today Elvira Hynds, RHIT has ... Cantata Health’s highly regarded customer support team focusing on initiatives to continuously improve ...
(Date:11/28/2018)... ... November 28, 2018 , ... ... to announce a new partnership with CME Master, a division of HealthMinds Consulting ... with expansion into South East Asia expected soon. This new collaboration will provide ...
(Date:11/28/2018)... ... November 29, 2018 , ... Physician Partners of America welcomes Neil Ellis ... will join Dr. Jorge Leal , as an interventional pain management specialist in ... Toronto, Canada, Dr. Ellis is double board-certified in Anesthesiology and Interventional Pain Medicine by ...
Breaking Medicine Technology:
Cached News: